Oncogenic activation of GTPase HRas (HRAS) and human epidermal growth factor receptor 2 (HER2) has been frequently found in breast cancers, leading to tumor initiation, progression, and metastasis [Fig. S1(a)].33–35. Here, ERBB2 is linked to breast carcinoma.